Revenue remains at a negligible $28.4K for 2026Q1, while the company continues to report deep operating losses with margins reaching -58.1% in the same period.
| Sales/Revenue | 34.55K | 6.2K | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 28.92K | 6.32K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 101.87% | - | - | - | - |
| Gross Profit | 5.63K | -116 | 0 | 0 | 0 | 0 |
| Gross Margin % | 16.3% | -1.87% | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 5.45M | 19.35M | 3.09M | 1.34M | 976.35K | 25.48K |
| OpEx % of Revenue | - | 312015.08% | - | - | - | - |
| Selling, General & Admin | 4.49M | 18.43M | 3.09M | 1.34M | 976.35K | 27.79K |
| SG&A % of Revenue | - | 297118.04% | - | - | - | - |
| Research & Development | 957.54K | 923.91K | 144.36K | 72.05K | 175.32K | 0 |
| R&D % of Revenue | - | 14897.03% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -144.36K | -72.05K | -175.32K | -2.32K |
| Operating Income | -5.44M | -19.35M | -3.09M | -1.34M | -976.35K | -25.48K |
| Operating Margin % | -15745.85% | -312016.95% | - | - | - | - |
| Operating Income Growth % | - | -526.52% | -130.5% | -37.25% | -3731.81% | - |
| EBITDA | -4.07M | -19.35M | -11.65M | 0 | 3.34M | 2.31K |
| EBITDA Margin % | -11787.82% | -312016.95% | - | - | - | - |
| EBITDA Growth % | 83.91% | -66.16% | - | -100% | 144436.48% | - |
| D&A (Non-Cash Add-back) | 2.02M | 0 | 0 | 1.34M | 0 | 27.79K |
| EBIT | -5.32M | -19.35M | -11.65M | 4.47M | 3.34M | 0 |
| Net Interest Income | -9.83M | -8.53M | -342.95K | 5.8M | 4.32M | 0 |
| Interest Income | 5.01K | 0 | 548.68K | 5.81M | 4.32M | 0 |
| Interest Expense | 9.84M | 8.53M | -892K | 8.97K | 0 | 0 |
| Other Income/Expense | -6.32M | -5.13M | -9.45M | 5.8M | 4.32M | 5 |
| Pretax Income | -11.76M | -24.48M | -12.54M | 4.46M | 3.34M | -25.48K |
| Pretax Margin % | -34039.68% | -394725.06% | - | - | - | - |
| Income Tax | 0 | 0 | 1.01K | 0 | 626 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.01% | 0% | 0.02% | 0% |
| Net Income | -11.76M | -24.48M | -12.54M | 4.46M | 3.34M | -25.48K |
| Net Margin % | -34039.68% | -394725.06% | - | - | - | - |
| Net Income Growth % | 54.78% | -95.27% | -380.85% | 33.65% | 13210.89% | - |
| Net Income (Continuing) | -11.76M | -24.48M | -12.54M | 4.46M | 3.34M | -25.48K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.87 | -16.38 | -18.17 | 9.31 | 3.72 | -0.04 |
| EPS Growth % | 73.23% | 9.85% | -295.17% | 150.27% | 10073.19% | - |
| EPS (Basic) | - | -16.38 | -18.17 | 9.31 | 3.72 | -0.04 |
| Diluted Shares Outstanding | 1.49M | 1.49M | 689.91K | 479.48K | 898.44K | 682.81K |
| Basic Shares Outstanding | 1.49M | 1.49M | 689.91K | 479.48K | 898.44K | 682.81K |
| Dividend Payout Ratio | - | - | - | - | - | - |
Imminent liquidity and insolvency risk
As reported in recent financial filings, ASBPW's revenue remains negligible at $28.4K for 2026Q1, confirming the company has yet to establish a repeatable commercial model or achieve meaningful market penetration for its diagnostic assays within the highly competitive biotechnology sector.
The sporadic and minimal revenue figures suggest that the company is currently operating in a pilot or experimental phase rather than a commercial one. Investors should monitor whether these small inflows represent sustainable service contracts or merely one-off research grants that fail to provide a foundation for future growth.
Based on the company's historical income statements, ASBPW's operating expenses, particularly SG&A, frequently dwarf revenue, with 2025Q1 SG&A alone reaching $15.3M, indicating a cost structure that is entirely decoupled from the firm's current ability to generate top-line results.
The massive disparity between overhead and revenue suggests a lack of expense discipline or an aggressive, perhaps premature, investment in infrastructure. This cost profile implies that the company is burning through capital at a rate that is unsustainable without a significant and immediate shift in operational efficiency.
According to the provided quarterly data, ASBPW exhibits extreme negative operating leverage, as evidenced by the 2026Q1 operating margin of -58.1% and historical troughs exceeding -500%, demonstrating that the company has failed to achieve any meaningful scale in its core diagnostic operations.
The inability to scale operating income relative to gross profit suggests that the company's fixed costs are too high for its current revenue base. This indicates that the business model may require a fundamental restructuring or a pivot to a different cost structure to achieve even basic operational viability.
As indicated by the persistent net losses and the depletion of cash reserves to approximately $1M, the company appears to be facing a potential going concern crisis, which short-sellers would likely highlight as a clear indicator of terminal financial distress.
While some may argue the company holds valuable intellectual property, the financial data suggests that the cost of maintaining this IP is rapidly exceeding the firm's ability to fund its own operations. Investors should consider whether the current valuation is supported by tangible assets or if the company is effectively a shell entity nearing a liquidity event.
Quick answers to the most common questions about buying ASBPW stock.
For fiscal year 2025, Aspire Biopharma Holdings, Inc. (ASBPW) reported total revenue of $0.0M.
Aspire Biopharma Holdings, Inc. (ASBPW) reported a net loss of $24.5M for the fiscal year ending 2025.
Aspire Biopharma Holdings, Inc. (ASBPW) reported an operating income of $-19.4M, resulting in an operating profit margin of -312016.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Aspire Biopharma Holdings, Inc. (ASBPW) generated $-0.0M in gross profit for the year, representing a gross profit margin of -1.9%. This demonstrates the company's core pricing power and production efficiency.